RELATED STUDY
Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders
Key Findings: The assigned medication was administered for 5 months. Significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and QOL was observed in the total study cohort, regardless of treatment assignment
Type of Study: Clinical Trial
Study Sample Size: 25
Study Result: Positive
Research Location(s): Israel
Year of Pub: 2018
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Sub-Ratio: 1:20 and 1:6 (THC:CBD)
Dosage: Taken over 5 mo, two CBD enriched 5% oil formulations were compared: one with 0.25% THC( 20:1 group), the other with 0.83% THC (6:1 group)
Citation: Libzon S, et al. Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. J Child Neurol. 2018; 33:565-571. doi: 10.1177/0883073818773028
Authors: Libzon S, Schleider LB, Saban N, Levit L, Tamari Y, Linder I, Lerman-Sagie T, Blumkin L
